What Transformation Has the Quit Smoking Drugs Market Undergone?
The quit smoking drugs market has seen considerable growth due to a variety of factors.
• The market for drugs to aid in smoking cessation has seen exponential expansion in the past few years. The market, which was valued at $39.26 billion in 2024, is projected to rise to $44.62 billion in 2025, exemplifying a compound annual growth rate (CAGR) of 13.7%. Factors that can be linked to this substantial growth seen in the historic period include health awareness programs, advancements in medical technology, government-led initiatives, integration of behavioral therapies, and changes in consumer attitudes.
What Is The Forecast For The Quit Smoking Drugs Template Market?
The Quit Smoking Drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for drugs used to quit smoking is predicted to rapidly expand in the forthcoming years, escalating to $79.99 billion in 2029 with a compound annual growth rate (CAGR) of 15.7%.
Factors influencing growth during this forecast period include ongoing investment in research and development, increasing demands for cessation aids, targeted marketing and public awareness campaigns, and advancements in pharmacotherapy. Significant trends anticipated for this period encompass personalized treatment strategies, a higher emphasis on health consciousness, the use of digital therapeutics and apps, the integration of behavioral therapy, and targeted educational and marketing efforts.
What Are The Essential Drivers Behind The Growth Of The Quit Smoking Drugs Market?
The rising tide of smoking habits is anticipated to boost the expansion of the market for quit-smoking medications in the future. Smoking involves inhaling and exhaling the vapour from combusted plant materials like tobacco, marijuana, hashish, among others. Drugs meant to assist in smoking cessation are effective in neutralising the desire for tobacco, thus helping individuals fight their smoking habit. These medications function by managing nicotine withdrawal symptoms, eventually facilitating successful quitting. As per data from Statistics Canada, a government agency in Canada, the output of cigarettes in July 2022 saw a 5.8% increase compared to June 2021. In addition, the overall cigarette sales witnessed a 1.3% rise from May 2022, peaking at 1.4 billion in June 2022. It can be inferred from these trends that the escalating addiction to smoking is positively impacting the growth of the quit-smoking drug market.
How Is The Global Quit Smoking Drugs Market Divided Into Key Segments?
The quit smoking drugs market covered in this report is segmented –
1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets
2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs
3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)
2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems
3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers
4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges
5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets
Pre-Book The Quit Smoking Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Quit Smoking Drugs Market?
In the quit-smoking drug market, product innovations have emerged as a key aspect in achieving market prominence. Major industry players have been concentrating on product innovation to fortify their market standing. For instance, Swedish Match AB, a tobacco company based in Sweden, made its mark in August 2022 by releasing ZYN Tobacco Gold, a travel retail nicotine pouch with a tobacco flavor. The Tobacco Gold pouches, offered in medium (3 mg) and strong (6 mg) strengths, have a sweet tobacco flavor which reminds one of dried fruit, wood, and caramel, fulfilling customer expectation as tobacco has become the favored flavor. This product caters to those smokers who wish to abstain from tobacco use, yet still enjoy a nicotine buzz in a smoke-free scenario. It presents a tobacco-free, smoke-free alternative for consumers who want to reduce their risk.
Who Are the Key Players In The Quit Smoking Drugs Market?
Major companies operating in the quit smoking drugs market include:
• 22nd Century Group
• Cipla Limited
• Dr. Reddy's Laboratories
• GSK Plc.
• Johnson & Johnson
• NJOY LLC
• Novartis AG
• Perrigo Company Plc
• Pfizer Inc.
• Philip Morris International
• Glenmark Pharmaceuticals Limited
• Zydus Cadila Healthcare Limited
• Rusan Pharma Ltd.
• BioCorRx Inc.
• CV Sciences Inc.
• Ennaid Therapeutics LLC
• Fertin Pharma A/S
• Gilla Inc.
• Hikma Pharmaceuticals PLC
• Innovus Pharmaceuticals Inc.
• IntelGenx Technologies Corp.
What Are The Regional Insights Into The Quit Smoking Drugs Market?
North America was the largest region in the quit smoking drugs market in 2024. The regions covered in the quit smoking drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
